NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
8 trialsNCT04359784 2025-10-23
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT04432506 2025-01-28
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03233776 2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2 Completed
NCT04099901 2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2 Completed
NCT02090101 2023-10-17
IRAFU
Centre Georges Francois Leclerc
Phase 2 Completed
NCT03578497 2021-01-27
FertIL
University Hospital, Basel, Switzerland
Phase 2 Completed
NCT00635154 2018-06-07
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
Mayo Clinic
Phase 2 Completed